David Staskin

Impact of vibegron on quality of life in men with overactive bladder receiving treatment for benign prostatic hyperplasia: patient-reported outcomes from the randomized placebo-controlled COURAGE trial

Abstract Background Men receiving pharmacologic treatment for benign prostatic hyperplasia (BPH) may experience reduced quality of life (QoL) owing to persistent overactive bladder (OAB) symptoms. Vibegron, a β 3 -adrenergic receptor agonist, was approved for OAB symptoms based o...